TY - JOUR
T1 - Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma
AU - Mariotti, S.
AU - Barbesino, G.
AU - Caturegli, P.
AU - Marinò, M.
AU - Manetti, L.
AU - Fugazzola, L.
AU - Pacini, F.
AU - Pinchera, A.
PY - 1994
Y1 - 1994
N2 - Increased concentrations of serum soluble interleukin-2 (IL-2) receptor (sIL-2R), a marker of T-lymphocyte activation, have been found in several metastatic solid tumors. To our knowledge, no information is available on serum sIL-2R in differentiated thyroid carcinoma (DTC). Aim of this study was to evaluate whether disease activity and/or thyroid status may affect circulating sIL-2R in DTC, since it is has recently been demonstrated that serum thyroid hormone concentration positively modulates circulating sIL-2R. DTC patients were divided into 3 groups: Group A: 48 patients without metastases or local recurrences; Group B: 16 patients with cervical lymph node metastases; Group C: 22 patients with distant metastases. All patients were evaluated after total thyroidectomy both off and on L-thyroxine (L-T4) therapy. Control group was composed by 20 healthy euthyroid subjects. sIL-2R was assayed by solid-phase ELISA. In the hypothyroid state, sIL-2R levels of Group A were significantly lower when compared to normal controls (256±130 vs. 461±186 U/ml, p2: 30.4, p910 U/ml) serum sIL-2R concentration off L-T4 therapy. No significant correlation between serum sIL-2R and serum thyroglobulin was observed both in hypothyroid (r=0.12, p=0.3) and in euthyroid (r=0.09, p=0.3) patients. No significant correlation was found between circulating sIL-2R and tumor histotype, duration of disease, previous amount of administered radioiodine and presence of antithyroid autoantibodies. In conclusion, the present study suggests that thyroid status and disease progression modulate serum sIL-2R. In patients free of disease, circulating sIL-2R appear to be strictly dependent on the thyroid status. In contrast, high serum sIL-2R was observed in some patients with metastatic DTC off L-T4 therapy, in spite of the hypothyroid state. This phenomenon is unrelated to several parameters of disease progression and its clinical meaning is unclear.
AB - Increased concentrations of serum soluble interleukin-2 (IL-2) receptor (sIL-2R), a marker of T-lymphocyte activation, have been found in several metastatic solid tumors. To our knowledge, no information is available on serum sIL-2R in differentiated thyroid carcinoma (DTC). Aim of this study was to evaluate whether disease activity and/or thyroid status may affect circulating sIL-2R in DTC, since it is has recently been demonstrated that serum thyroid hormone concentration positively modulates circulating sIL-2R. DTC patients were divided into 3 groups: Group A: 48 patients without metastases or local recurrences; Group B: 16 patients with cervical lymph node metastases; Group C: 22 patients with distant metastases. All patients were evaluated after total thyroidectomy both off and on L-thyroxine (L-T4) therapy. Control group was composed by 20 healthy euthyroid subjects. sIL-2R was assayed by solid-phase ELISA. In the hypothyroid state, sIL-2R levels of Group A were significantly lower when compared to normal controls (256±130 vs. 461±186 U/ml, p2: 30.4, p910 U/ml) serum sIL-2R concentration off L-T4 therapy. No significant correlation between serum sIL-2R and serum thyroglobulin was observed both in hypothyroid (r=0.12, p=0.3) and in euthyroid (r=0.09, p=0.3) patients. No significant correlation was found between circulating sIL-2R and tumor histotype, duration of disease, previous amount of administered radioiodine and presence of antithyroid autoantibodies. In conclusion, the present study suggests that thyroid status and disease progression modulate serum sIL-2R. In patients free of disease, circulating sIL-2R appear to be strictly dependent on the thyroid status. In contrast, high serum sIL-2R was observed in some patients with metastatic DTC off L-T4 therapy, in spite of the hypothyroid state. This phenomenon is unrelated to several parameters of disease progression and its clinical meaning is unclear.
KW - cytokines
KW - Interleukin-2
KW - interleukin-2 receptor (soluble)
KW - thyroid carcinoma
KW - thyroid disease
UR - http://www.scopus.com/inward/record.url?scp=0028589544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028589544&partnerID=8YFLogxK
U2 - 10.1007/BF03347792
DO - 10.1007/BF03347792
M3 - Article
C2 - 7745234
AN - SCOPUS:0028589544
VL - 17
SP - 861
EP - 867
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 11
ER -